Women get less treatment to prevent heart attack; study

25 May 2008

A new study has found that women with coronary artery disease are significantly less likely than men to be treated with medications to prevent heart attacks. As a result, WomenHeart - A US national coalition for women with heart disease - is calling on doctors to take extra precautions to make sure that women are getting the care that they need.

"This study should serve as a wake-up call to doctors and women alike," said Lisa Tate, WomenHeart chief executive, adding: "heart disease is the leading cause of death of American women. Clearly, too [many] women are not getting the medical care that they need."

The study, published this month in the journal Heart, was based on data from 25,755 men and women who had a heart attack or chest pain between 1999 and 2006. All the patients had an angiogram to check for blockages in their heart's blood vessels. Among heart patients, women were significantly less likely than men to receive medications such as beta blockers, statins and ACE inhibitors - which experts say are crucial to preventing further heart problems, the study's authors said. Female patients also were less likely to get treatments to open their blood vessels, the research found.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight